A trial looking at BNT327 and chemotherapy for non small cell lung cancer (BNT327-06)

Cancer type:

Lung cancer
Non small cell lung cancer
Secondary cancers

Status:

Open

Phase:

Phase 2/3

This trial is looking at a drug called BNT327 in combination with standard chemotherapy Open a glossary item.

It is for people whose non small cell lung cancer has spread and they:

  • are having their first treatment for advanced Open a glossary item non small cell lung cancer
  • can’t have surgery or radiotherapy with the aim to cure 

More about this trial

Chemotherapy is one of the main treatments for non small cell lung cancer (NSCLC) that has spread. A standard combination of chemotherapy for NSCLC includes pemetrexed and carboplatin or paclitaxel and carboplatin. You might have this alongside an immunotherapy Open a glossary item such as pembrolizumab.

Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug Open a glossary item. It works in 2 ways. It aims to help the immune system Open a glossary item to find and kill cancer cells. Cancer cells need a blood supply to fuel their growth. BNT327 also aims to stop cancer cells from forming new blood vessels. 

Doctors are exploring whether adding BNT327 to standard chemotherapy will help it to work better. But they don’t know this for sure, so they want to find this out. First, they need to find the best dose of BNT327 to have alongside chemotherapy. 

There are 2 parts to this trial. The phase 2 part is looking at the best dose of BNT327 to have. When they find this dose then the larger phase 3 part trial will open. We will add details about the phase 3 part when it opens. 

Everyone in phase 2 has BNT327 in combination with chemotherapy. 

The main aims of the trial are to find:

  • the best dose of BNT327 to have with chemotherapy
  • how safe BNT327 is
  • how well BNT327 works
  • what happens to BNT327 in the body
  • how treatment affects your quality of life Open a glossary item

Who can enter

The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. 

Who can take part

You may be able to join this trial if all of the following apply. You:

  • have non small cell lung cancer (NSCLC) that has spread into surrounding tissues and you can’t have surgery or radiotherapy to treat it with the aim to cure. This is stage 3B or 3C lung cancer. Or you have cancer that has spread to other parts of the body. This is stage 4 lung cancer.
  • have at least one area of cancer that your doctor can measure on a scan
  • are fit and active but might not be able to do heavy physical work (ECOG performance status 0 or 1)
  • have satisfactory blood test results
  • are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant. You must also be willing not to freeze or donate eggs or donate sperm during the trial and for a period after.
  • are at least 18 years old 

Who can’t take part

Cancer related
You cannot join this trial if any of these apply. You:

  • have a mixture of small cell and non small cell cancer cells
  • have an EGFR gene change (mutation Open a glossary item) or an anaplastic lymphoma kinase (ALK) gene change in your lung cancer cells. Your doctor will know this.
  • have symptoms of cancer that have spread to the brain. You can take part if you have had treatment, the cancer has been stable and you stopped taking steroids Open a glossary item within 10 days of starting trial treatment.
  • have already had certain targeted cancer drugs Open a glossary item, immunotherapies Open a glossary item, BNT327 or similar drugs or platinum chemotherapy Open a glossary item. This would have been treatment that you had before or after surgery for lung cancer. You can take part if you had only surgery for lung cancer.
  • have had another cancer in the last 5 years. You can take part if you had successfully treated carcinoma in situ Open a glossary item of the cervix, ductal carcinoma insitu Open a glossary item of the breast, early Open a glossary item bladder cancer, early prostate cancer or non melanoma skin cancer Open a glossary item or papillary thyroid cancer.
  • had any serious side effects caused by immunotherapy for another type of cancer that meant you had to stop treatment
  • are taking an experimental drug or using a device as part of another clinical trial. This is if it is within 28 days of being put in a treatment group for this trial.

Medical conditions
You cannot join this trial if any of these apply. You:

  • have had a heart attack or a significant heart problem Open a glossary item within the last 6 months. Your doctor checks your heart before you join the trial.
  • have had a stroke Open a glossary item in the last 6 months 
  • have high blood pressure that isn’t well controlled with medication
  • have diabetes that isn’t well controlled with medication
  • have an active autoimmune condition Open a glossary item or you have had one in the past apart from certain ones. Your doctor will know about this.
  • have moderate to severe side effects from past treatments. You can take part if you have hair loss.
  • have had antibiotics as a drip into a vein within 2 weeks of trial treatment
  • have had steroids within 2 weeks of starting trial treatment unless it was a low dose. Your doctor will know this.
  • have a blockage in a large vein in the chest called the superior vena cava. Your doctor will know about this. 
  • have or had scarring on the lungs or inflammation of the lungs (pneumonitis Open a glossary item) that needed treatment in the past
  • have symptoms of spinal cord compression Open a glossary item
  • have HIV, an active hepatitis B or active hepatitis C infection that isn’t well controlled with medication or you have active tuberculosis Open a glossary item
  • have had major surgery, a significant traumatic injury or an invasive dental procedure such as dental implants within 28 days of starting trial treatment or you plan to have surgery during the trial
  • have had a stem cell transplant Open a glossary item using donor stem cells or an organ transplant in the past
  • have a serious wound that isn't healing, an ulcer or bone fracture within 6 months of joining the trial. You can’t take part if you had or have a risk of a fistula Open a glossary item in your abdomen Open a glossary item, an abnormal opening between the windpipe and the food pipe, a hole or tear in the gut or a collection of pus in the abdomen in the last 6 months.
  • have had a major bleeding problem or you have a risk of developing this. Your doctor will know this.
  • have a collection of fluid on your lungs, around your heart or in your tummy (abdomen) that needs to be drained often. You might be able to take part if these conditions are stable.
  • have another medical condition or mental health condition that could affect you taking part or there is another reason the trial team don’t think you will be suitable

Other
You cannot join this trial if any of these apply. You:

  • are allergic to any of the treatments in the trial or anything they contain
  • have had a live vaccination Open a glossary item within 30 days of starting treatment. You can take part if you have had the seasonal flu vaccine or the approved Covid-19 vaccines as these aren’t live.
  • are pregnant or breastfeeding or you are planning to become pregnant during the trial and for a period after

Trial design

This is a phase 2/3 trial. It is taking place worldwide. The team need 982 people to take part in total. 

Only the phase 2 part of the trial is open. This is looking at the best dose of BNT327 to have with standard chemotherapy. When they find this dose, then the larger phase 3 part of the trial will open. We will add the details about this when it opens.

Phase 2 part
The team need 40 people to join phase 2. This includes 10 people from the UK. 

The team are looking at 2 different doses of BNT327. A computer puts you into a treatment group at random. Neither you nor your doctor will be able to decide which dose you have. You and your doctor will know which dose you are having. 
There are 2 groups. You have 1 of the following:

  • dose level one of BNT327 and standard chemotherapy
  • dose level two of BNT327 and standard chemotherapy

You have treatment in cycles Open a glossary item. To begin with, everyone has 4 cycles of treatment. You have BNT327 and carboplatin with either pemetrexed or paclitaxel chemotherapy. You have this once every 3 weeks. This takes 12 weeks in total.

You have all your treatment as a drip into a vein. BNT327 takes about 90 minutes each time. The trial doctor will tell you which chemotherapy drugs you have and how long each one takes.

Your doctor or nurse will monitor you closely the first 2 times you have BNT327. This includes for 3 hours after the infusion has finished. They will treat any problems straight away.

You then have more treatment for up to 2 years. You have the same dose of BNT327 that you had before. Some people also have pemetrexed chemotherapy. Your doctor will tell you if this applies to you. You have treatment once every 3 weeks. You have this for up to 2 years as long as the treatment is working and the side effects aren’t too bad.

Samples for research 
The researchers might ask to take a tissue sample (biopsy Open a glossary item) if there isn’t a previous sample that they can use. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.

They plan to use the samples to:

  • see what happens to BNT327 in the body 
  • see how well the treatment is working
  • look for substances called biomarkers Open a glossary item to help work out why treatment might work for some people and not for others
  • check if you are developing antibodies Open a glossary item to BNT327
  • look for circulating tumour DNA (ctDNA Open a glossary item) in the bloodstream

The team will also ask your permission to store some samples for future research. You don’t have to agree to this future research. It won’t affect you taking part in the rest of the trial. 

Quality of life
The trial team ask you to fill out some questionnaires:

  • before you start treatment
  • at set times during treatment
  • at set times after treatment 

The questionnaires ask about side effects and how you’ve been feeling. This is called a quality of life study.

Hospital visits

You see the doctor for a physical examination Open a glossary item and you have some tests before you can take part in the trial. These include

You might have a bone scan if your doctor thinks this is necessary. 

During treatment you see the doctor regularly. This is for blood tests and to see how you are.

Trial scans 
You have a CT scan or MRI scan:

  • every 6 weeks for 6 months
  • every 9 weeks for the next 6 months and then
  • every 3 months after that

You stop having the scans as part of the trial if your cancer gets worse.

Follow up visits
You see the trial team when you stop treatment for a check up 7 days later and then at:

  • 1 month
  • 3 months

After that, the trial team will call you once every 3 months to see how you are getting on. They do this for up to 2 years.

Side effects

The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.

BNT327 can affect the immune system Open a glossary item. This may cause inflammation Open a glossary item and other reactions in different parts of the body. For many people the inflammation and reactions are not too bad. For some people they can cause serious side effects. 

These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for.
 
If you have any of these side effects tell your doctor or nurse as soon as possible. You should tell them that you are on or have been on an immunotherapy.

 

BNT327 is a new drug that has not been approved, so we don’t know what all the side effects are. The most common effects of BNT327 we know about so far include:

  • a reaction to the drug which occurs during or soon (within a few hours) after having it. This is called an infusion reaction. Signs include a high temperature, chills, shortness of breath, pain, feeling or being sick, feeling dizzy and faint due to low blood pressure or getting headaches due to high blood pressure.
  • high levels of protein in the urine
  • high blood pressure
  • bruising and bleeding
  • delayed wound healing 

We have more information about:

Location

Birmingham
Brighton
Cardiff
Glasgow
Hull
Liverpool
London
Manchester
Middlesbrough
Oxford
Preston
Sheffield
Southampton
Sutton
Wolverhampton

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Yvonne Summers

Supported by

BioNTech SE

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

20018

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think